Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alexander K. Stewart, M.D.
Mayo Clinic
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- University of California, San Francisco
San Francisco, California, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Ohio State University
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2010
- Primary completion
- 30 Sept 2014
- Completion
- 30 Nov 2014
- Last update posted
- 25 May 2016
- Registered enrollment
- 26
- Registry id
- NCT01034553
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.